BioRestorative Therapies, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its BRTX-100 program for treating chronic lumbar disc disease (cLDD).
MELVILLE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc (BRTX). (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results